Gyros introduces new product for high concentration protein quantification


Gyros announced today that it has extended its product range with a new compact disc (CD) microlaboratory – Gyrolab Bioaffy 20 HC – for dilution-free protein quantification in the grams per liter range.

When quantifying proteins in high concentrations, current technologies, such as ELISA, require extensive dilution of samples in order to bring them into the technology’s measurable range. This is cumbersome and time consuming for scientists and increases the risk of quantification errors. By using very small sample volumes and a high-capacity capture column, Gyrolab Bioaffy 20 HC increases the measurement range, allowing scientists to quantify proteins in the grams per liter range without the need for any pre-assay, sample dilution.

Both the new Gyrolab Bioaffy 20 HC and the existing Gyrolab Bioaffy 200 (for high sensitivity assays when detecting low concentrations) CD microlaboratories are run on the same fully automated instrument, Gyrolab® Workstation. As such, scientists are able to run a diverse range of applications all using a single instrument. The open design principle underlying the platform provides very wide flexibility in the choice of target protein and allows experimental set-up to be designed on a day-to-day basis.

An example application where the introduction of Gyrolab Bioaffy 20 HC can greatly support the work of scientists is in process development for the production of protein-based drugs (biopharmaceuticals), such as monoclonal IgG. The combination of Gyrolab Bioaffy 20 HC and Gyrolab Bioaffy 200 can be used to increase the efficiency of biopharmaceutical process development by quickly and accurately quantifying drug product and host cell proteins at concentrations relevant for the entire purification process, from cell supernatant to purified product.

Commenting on the launch, Jan Würtz, Gyros CEO, said, “The new CD microlaboratory is an important addition to our product line and extends the value of our offering to our growing customer base. It also shows the versatility of our technology to meet different application needs. Obviously, it strengthens our position for new sales activity as well, and means that we can now offer a complete, single system solution with an extremely broad measurement range – something that is particularly well suited to biotherapeutic applications.”

For Gyros AB

Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: /

Notes to editors:
About Gyros (

Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.

Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.

The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.